Elias Jabbour, MD
Executive Editor
Elias Jabbour, MD, is the D.B. Lane Cancer Research Fund Distinguished Professor in Leukemia Research, the Section Chief of Acute Lymphoblastic Leukemia, and Professor of Medicine in the Department of Leukemia, Division of Cancer Medicine, at MD Anderson Cancer Center in Houston.
Articles by Elias Jabbour, MD
The 2024 Society of Hematologic Oncology (SOHO) Annual Meeting will take place September 4-7 in Houston, Texas.
Elias Jabbour, MD, gives MDS highlights from EHA 2024.
The panel discussed ALL treatment, associated toxicities, and the possibility of a chemotherapy-free approach.
In this executive editor's message, Elias Jabbour, MD, writes about redefining leukemias as curable or less curable.
The panel mainly discussed frontline tyrosine kinase inhibitors for the treatment of chronic phase CML.
Elias Jabbour, MD, discusses the latest news and novel therapies in CLL.
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.
The Blood Cancers Today Editorial Board offers their thoughts on the past year.
Elias Jabbour, MD, discusses the most burning questions in acute lymphoblastic leukemia (ALL).
Dr. Jabbour presented data from the study at the Eleventh Annual Meeting of SOHO.
September is always an exciting time for SOHO members as the month brings the Annual Meeting in Houston, Texas.
The Blood Cancers Today Editorial Board reflects on the latest news in the field so far in 2023.
Blood Cancers Today Associate Elias Jabbour, MD, gives an update from the 2023 EHA Congress.
We went from survival of 10% to 90% and from full-fledged chemotherapy and transplant to a chemotherapy-free regimen.
As 2022 came to a close, the Blood Cancers Today Editorial Board shared their highlights from the year.
Elias Jabbour, MD, chats with The HemOnc Pulse host Chadi Nabhan, MD, MBA, FACP, about ALL treatment advances at ASH 2022.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.